Clinical Trial Update: Iressa v BSC (Best Supportive Care) in First Line NSCLC [Phase 2, Phase 3]

View source ↗

Summary

Phase 2 and Phase 3 trials comparing Iressa (gefitinib) to Best Supportive Care in first-line non-small cell lung cancer have been completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Iressa (gefitinib)

Snippet

Sponsor: AstraZeneca | Conditions: NSCLC | Phase 2, Phase 3 | Status: COMPLETED